Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Founder operating in the Health Care space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Noubar Afeyan
Founder & CEO of Flagship Pioneering
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm’s VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
Follow Noubar Afeyan:
About BIND Therapeutics, Cogen Therapeutics, Cygnal Therapeutics, Ensemble Therapeutics, Flagship Pioneering, Generate Biomedicines, Harvard Business School, Indigo, Joule Unlimited Technologies, Laronde, Massachusetts Institute of Technology, Moderna Therapeutics, Omega Therapeutics, Permeon Biologics, Ring Therapeutics, Rubius Therapeutics, Seres Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Geraldine Harriman
CSO & Co-Founder of HotSpot Therapeutics
Geraldine Harriman is the Co-Founder and Chief Scientific Officer of HotSpot Therapeutics.
Follow Geraldine Harriman:
About HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Nick Lydon
Scientific Founder of Blueprint Medicines
Nick Lydon, Ph.D., is a scientific founder of Blueprint Medicines. Before founding his current consulting company, Granite Biopharma, LLC, Dr. Lydon served as vice president, small molecule drug discovery at Amgen. Prior to joining Amgen, he founded and led Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, a number of which are now advancing through clinical development. Kinetix was acquired by Amgen in 2000. Prior to Kinetix, Dr. Lydon worked at CIBA-GEIGY, in Basel, Switzerland, where he was responsible for the protein kinase inhibitor program. He and his team identified a number of protein kinase inhibitors. The most advanced drug from this program is Gleevec®, a selective Bcr-Abl inhibitor for the treatment of chronic myelogenous leukemia (CML). Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation, where his research involved studies on recombinant alpha, beta and gamma interferons. In 2009, Dr. Lydon was awarded the Lasker-DeBakey Award for Clinical Medical Research for his work on developing Gleevec®, converting a fatal cancer into a manageable chronic condition. Other awards include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain Memorial Award, and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation for his contributions to the discovery and development of Gleevec®. Dr. Lydon earned a B.S. in biochemistry from the University of Leeds, England, and received his Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland. His thesis involved research work on adenylate cyclase and cAMP dependent protein kinase. Dr. Lydon served as an advisor and member of the board of directors of Ambit BioScience from 2004 to 2009 and assisted in the development of AC220, a FLT3 kinase inhibitor in Phase 2 clinical development in relapsed/refractory acute myeloid leukemia (AML).
Follow Nick Lydon:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Boris Lipchin
Founder and CEO of BRIO Systems
Boris Lipchin, co-founder and CEO of Brio Systems, Inc.. Boris was previously a co-founder and CTO of Airmada, Inc. before Airmada four years as a flight software engineer, launch operator and GN&C engineer for SpaceX.
Follow Boris Lipchin:
About Brio, BRIO Systems, Techstars: BRIO Systems offers a complete COVID-19 testing system to help employers keep teams safe and businesses on track.
Michael Anstey
Co-Founder and Chief Operating Officer of Proteorex Therapeutics Inc.
Michael Anstey is an Investment Director specialising in healthcare investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A. Michael was co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford. Michael sits on the board of Bicycle Therapeutics.
Follow Michael Anstey:
About Cambridge Innovation Capital, Proteorex Therapeutics Inc.: Expanding horizons to find cures
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Khaled Kteily
Founder & CEO of Legacy
Khaled Kteily is the Founder & CEO of Legacy, a digital fertility clinic for men helping change the outdated view that fertility is a “women’s issue”. Legacy is a graduate of Harvard’s Innovation Labs and Y Combinator, has raised over $20M from top-tier investors like FirstMark Capital & Bain Capital Ventures, as well as celebrities like Justin Bieber and DJ Khaled. The company works with leading insurers, military partners, and clinics in additions to its Direct to Consumer offering. A former healthcare consultant at Oliver Wyman in Toronto, Khaled studied public policy at the Harvard Kennedy School, where he received a full scholarship and graduated with distinction. He previously graduated with a triple concentration from McGill University in Montreal, Canada. Khaled is a member of the Young Presidents Organization (YPO), is an Aspen Ideas Health Scholar, and a World Economic Forum Global Leadership Fellow. He was recently recognized as 40 under 40 by the Arab America Foundation. He serves on the boards of the Harvard Kennedy School’s Center for Public Leadership (Alumni Council) and the Harvard Arab Alumni Association.
Follow Khaled Kteily:
About Legacy: Legacy is a digital fertility clinic for men, founded at Harvard & backed by Y Combinator, FirstMark Capital, Bain Capital and celebrities.
Amy Schulman
Executive Chairman & Co-Founder of Lyndra Therapeutics
Amy Schulman is the Chief Executive Officer at Arsia Therapeutics since August 2014. Arsia, a biotechnology company focused on improving patients’ lives through new modes of drug delivery, and a venture partner at Polaris, a leading venture capital firm with approximately 4 billion under management in August of 2014. Amy joined Polaris Partner’s Boston office as a Healthcare Venture Partner in 2014, simultaneously assuming the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company. In July 2015 Amy co-founded Lyndra where she is Chief Executive Officer and President. Amy is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures. Amy joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014. Prior to that, Amy led Pfizer Inc.’s $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum and Chapstick. Amy also served as Executive Vice President and General Counsel of Pfizer Inc. Key accomplishments include: revitalization of the ChapStick brand; regulatory filing for Lipitor OTC; rapid growth of Emergen-C and increased Europe profitability. Amy originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth, the largest pharmaceutical acquisition in history. In 2009, Amy spearheaded an innovative approach to engaging outside counsel and became recognized as a leading voice for transforming the billable-hour model and for redefining the value of legal services. Before joining Pfizer, Amy was a Partner at DLA Piper, where she was a Member of the Board and Executive Policy Committees and built and led the international law firm’s mass tort and class-action practice handling some of the most complex legal, scientific and regulatory challenges facing the world’s largest and most reputable companies, including Kraft, Altria, Cisco, GE Healthcare and Pfizer. Amy began her career in litigation with Cleary Gottlieb Steen & Hamilton. Amy’s accomplishments have earned her accolades from leading publications and organizations. In 2013 Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer named her one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.” Amy also has been recognized by The American Bar Association, which honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. In 2009 Forbes magazine included her on its inaugural list of “The World’s Most Powerful Women.” Amy serves on the Boards of Directors of Alnylam Pharmaceuticals, Arsanis, Biosciences, Arsia Therapeutics, BIND Therapeutics, Blue Buffalo, Lyndra, and SQZ Biotech. A Phi Beta Kappa Graduate of Wesleyan University, Amy earned her J.D. from Yale Law School in 1989.
Follow Amy Schulman:
About Arsia Therapeutics, Harvard Business School, Lyndra Therapeutics, Polaris Partners, Suono Bio: Lyndra Therapeutics is a novel technology platform reinventing medicine for a healthier world.
Sammy Khalifa
Co-Founder and CTO of Vicarious Surgical
Follow Sammy Khalifa:
About Vicarious Surgical: Vicarious Surgical improves the lives of patients and surgeons by giving access to high quality care through the use of surgical robotics.
Alicia Chong Rodriguez
Co-Founder and CEO of Bloomer Health Tech
Alicia Chong Rodriguez is the founder and CEO of Bloomer Tech. She holds two master’s degrees in engineering and management/integrated design and electrical engineering and computer science (EECS) from Massachusetts Institute of Technology (MIT).
Follow Alicia Chong Rodriguez:
About Bloomer Health Tech: Bloomer Tech uses everyday fabrics and machine learning for personalized detection, monitoring, and treatment of chronic diseases.
Allen Lin
Co-Founder and CSO of Oncolinx
Follow Allen Lin:
About Harvard University, Oncolinx: Oncolinx is developing antibody-drug conjugates.
Tom Simmons
Founder & CEO of Supplant
Tom has over 10 years of experience in carbohydrate biochemistry. He formerly held fellowships at the University of Cambridge and at the World Economic Forum and has advocated sugar reduction initiatives through Sky News and Channel 4 television appearances.
Follow Tom Simmons:
About Cambridge Judge Business School, Supplant: Supplant is a biotechnology platform that makes sugar substitutes.
Shinta Nurfauzia
Co-Founder & CEO of Lemonilo
Shinta Nurfauzia is Co-Founder & CEO at Konsula.
Follow Shinta Nurfauzia:
About Lemonilo: Lemonilo is a curated marketplace for healthy food and cosmetics.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Oliver Armitage
Co-Founder & CSO of BIOS
Oliver Armitage is Co-Founder and Chief Scientific Officer at BIOS, a leading neural engineering startup. Oliver has always had a vision that the human body could be repaired or made better through augmentative technology and how that can be used to improve people’s lives. He studied for his PhD at the University of Cambridge in Bioengineering, working in the world-renowned Nanoscience Centre. He specializes in tissue interfaces and engineering to allow technology to be fused with the body. Oliver was recently named to Forbes 30 Under 30 2018.
Follow Oliver Armitage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Mark Kotter
Founder/CEO of bit.bio
Mark Kotter is the founder and CEO of bit.bio.
Follow Mark Kotter:
About bit.bio: Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.
Giulio Ruffini
President, CTO, Co-Founder of Neuroelectrics
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders, and improves overall brain health.
Thomas Schuetz
Co-Founder of Audentes Therapeutics
Dr. Schuetz, M.D., Ph.D., is the co-founder of Audentes Therapeutics and has served as a member of the board of directors since July 2013. Dr. Schuetz also provided consulting services to Audentes from July 2012 to June 2013. Dr. Schuetz is currently the Chief Executive Officer of Compass Therapeutics, LLC. Previously, Dr. Schuetz was a Venture Partner at OrbiMed. Dr. Schuetz served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has also served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz also serves on the board of directors of Relypsa, Inc. and Glypharma, Inc. Dr. Schuetz holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.
Follow Thomas Schuetz:
About Audentes Therapeutics, Compass Therapeutics, Inc.: Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Venky Soundararajan
Co-Founder & Chief Scientific Officer of nference
Follow Venky Soundararajan:
About nference: nference.inc, provides an AI based software platform that synthesizes siloed biomedical knowledge for insights and makes it computable.
Laura D’Asaro
Co-Founder & CEO of Chirps Chips (Six Foods)
Follow Laura D’Asaro:
About Chirps Chips (Six Foods): Chirps Chips is a creating edible insect foods for healthyeating and sustainability.
Jonathan Zhao
Co-Founder and Chairman of Hangzhou Just Biotherapeutics (Just China)
Asia strategy across small molecule, biologics and vaccine. He had also served as the interim head of Pfizer’s Bio-enhancement Development Unit during 2009-2010 in charge of the biosimilar and biobetter strategy development and business operation. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), PhD. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.
Follow Jonathan Zhao:
About Hangzhou Just Biotherapeutics (Just China), Transcenta: Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Laurence Bargery
Co Founder & CTO of AccuRx
Laurence Bargery is a Co-founder & CTO at accuRx.
Follow Laurence Bargery:
About AccuRx: AccuRx is on a mission to bring patients and their healthcare teams together.
Glenn Robertelli
Co-Founder & Chief Operating Officer of Admetsys
Follow Glenn Robertelli:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Mehmet Toner
Founder of Torpedo Diagnostics
Mehmet Toner is the Helen Andrus Benedict Professor of Bioengineering at the Massachusetts General Hospital, Harvard Medical School, and Harvard-MIT Health Sciences & Technology. He is internationally recognized for his research at the interface of nanotechnology, microsystems engineering, microfluidics, and applications in clinical medicine. Dr. Toner was born in Istanbul, Turkey. He obtained his undergraduate degree in mechanical engineering at the Istanbul Technical University, and his master’s degree and doctorate in Mechanical Engineering at MIT. He is the author of more than 300 original scientific and technical publications, and an inventor on more than 30 patents. Dr. Toner is a pioneer in the development of technologies to isolate extremely rare cells from blood, including circulating tumor cells. He is the founding Director of the NIH BioMicroElectroMechanical Systems Center, a nationwide center exploring the applications of microfluidics and nanotechnology in clinical medicine and life sciences. His work in cancer was awarded the Quantum grant from NIH as part of the “moon shot” program. His work has resulted in the formation of multiple companies servicing clinical diagnostics and biotechnology.
Follow Mehmet Toner:
About Massachusetts General Hospital, Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Daniel Haber
Founder of Torpedo Diagnostics
Daniel Haber is the Director of Massachusetts General Hospital (MGH) Cancer Center, the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute (HHMI). He earned his BS and MS degrees from Massachusetts Institute of Technology (MIT), and his MD and PhD from Stanford. He completed his residency in internal medicine at MGH, his clinical fellowship in oncology at Dana Farber Cancer Institute, and his postdoctoral training at MIT, before joining the MGH faculty in 1991. Dr. Haber is known for his research in cancer genetics, including the discovery of genes implicated in the pediatric kidney cancer Wilms Tumor, the prevalence of founder BRCA mutations in young women of Ashkenazi descent. In 2004, his laboratory identified specific mutations in the epidermal growth factor receptor (EGFR) gene that underlie exquisite sensitivity to targeted kinase inhibitors, a milestone in the development of precision oncology targeting genetically-identified subsets of common epithelial cancers. The MGH Cancer Center now conducts a broad range of first-in-human clinical trials of targeted anti-cancer agents. Dr. Haber’s research is currently focused on the use of circulating tumor cells (CTCs) as a non-invasive “liquid biopsy” to detect and interrogate cancer cells at different stages of treatment response and disease progression, a project for which he and his close collaborator Dr. Mehmet Toner were awarded a Stand Up To Cancer Dream Team Award. Dr. Haber is a member of the National Academy of Medicine (Institute of Medicine), the American Academy of Arts and Science (AAAS), the Association of American Physicians (AAP), and the American Society for Clinical Investigation (ASCI).
Follow Daniel Haber:
About Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Chris Mason
Founder & Chief Scientific Officer of Avrobio
Chris Mason is the Founder & Chief Scientific Officer at AVROBIO .
Follow Chris Mason:
About Avrobio, Cell & Gene Therapy, Krystal Biotech, Ori Biotech, University College London (UCL): Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Jeffrey Medin
Scientific Founder of Avrobio
Jeffrey received his PhD in Biochemistry from the University of Kentucky. He then trained at the NIH working on gene transcription and gene transfer/therapy. He was recently a Senior Scientist at the University Health Network and a Full Professor at the University of Toronto. In January 2016, Jeffrey started a new position as the MACC Fund Endowed Professor in the Department of Pediatrics at the Medical College of Wisconsin in Milwaukee. He is also Vice Chair of Research Innovation for the Department of Pediatrics, Research Director within the Section of Pediatric Hematology/Oncology, and GMP Facility Director.
Follow Jeffrey Medin:
About Association of Pediatric Hematology/Oncology Nurses, Avrobio, GMP Securities, Medical College of Wisconsin: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Christopher Paige
Scientific Founder of Avrobio
Christopher earned a PhD in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He became a Member of the Basel Institute for Immunology in Switzerland in 1980 where he worked until joining the Ontario Cancer Institute as a Senior Scientist in 1987. In 1990, Christopher became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1997, he returned to OCI, now part of the University Health Network, to assume the role of Vice President, Research at UHN. Christopher is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.
Follow Christopher Paige:
About Avrobio, University of Toronto: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Christopher J. P. Velis
Founder of Audax Medical
Christopher Velis is the founder of [MedCap Funds](https://www.crunchbase.com/organization/medcap#/entity), a private equity firm specializing in investments in middle markets, mature, turnarounds, buyouts, mezzanine, and bridge financings. He previously founded Audax Medical Technology. Velis holds a bachelor’s degree in economics and psychology from the University of Massachusetts and an MBA from Boston University.
Follow Christopher J. P. Velis:
About Arctic Fox Biomedical, Audax Medical, Auris Health, BOA Biomedical, MedCap Funds, MedCap Funds, Miraki Innovation: Audax Medical develops instrumentation and orthopedic biomaterials for the treatment of degenerative bones and musculoskeletal tissue.
Rajesh Devraj
CSO & Co-Founder of Disarm Therapeutics
Follow Rajesh Devraj:
About Atlas Venture, Disarm Therapeutics, Rectify Pharmaceuticals: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Edmund Sybertz
Founder of Lysosomal Therapeutics
Ted Sybertz, Ph.D., held various research leadership positions at Schering Plough, Geltex and Genzyme, focusing on cardiovascular and CNS diseases. At Genzyme, he played a leadership role in discovery and preclinical development of the glucosyl ceramide synthesis inhibitor, eliglustat. He has been associated with the discovery and introduction of over 20 molecules into clinical development, six of which were ultimately approved.
Follow Edmund Sybertz:
About Lysosomal Therapeutics: Lysosomal Therapeutics deliver cures for neurodegenerative diseases.
Jonathan Ng
Founder and CEO of Iterative Scopes
Jonathan Ng is the founder and CEO of Iterative Scopes.
Follow Jonathan Ng:
About Iterative Scopes: Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space.
Jennifer Hersch
Co-Founder & Director of Ethos
Follow Jennifer Hersch:
About Ethos: ETHOS is the ultimate yoga fitness hybrid experience with all one needs.
Jacob Rothman
CEO and Co-Founder of Perch
Co-Founder and CEO of Perch. Trying to revolutionize fitness technology. Learning something new everyday. MIT Grad.
Follow Jacob Rothman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
Nathan Rodman
CTO and Co-Founder of Perch
Nathan Rodman and Jacob Rothman founded Perch in July 2016, since which Nate has been serving as its chief technology officer.
Follow Nathan Rodman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
Derrick Rossi
Founder of Intellia Therapeutics
In 2010, Dr. Rossi discovered a groundbreaking method to reprogram skin cells into stem cells utilizing messenger molecules. His novel technique eliminated the risk of cancer posed by previous methods and sparked a push to develop cellular and molecular therapeutic products using the technologies he developed. More recently, Dr. Rossi and colleagues again innovated in the stem cell field by applying the CRISPR/Cas9 system to generate hematopoietic stem cells resistant to HIV infection. Dr. Rossi continues to study CRISPR for application in human therapeutics.
Follow Derrick Rossi:
About Convelo Therapeutics, Intellia Therapeutics, Moderna Therapeutics, Stelexis Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Rodolphe Barrangou
Co-Founder of Intellia Therapeutics
Rodolphe Barrangou is an Associate Professor of Food, Bioprocessing and Nutrition Sciences at North Carolina State University. His lab focuses on the biology and genetics of CRISPR/Cas immune systems in bacteria. He also serves on the Board of Directors of Caribou Biosciences. Rodolphe was previously a Director of Research and Development at DuPont and Danisco. While with Dansico, he was part of the team that initially established the adaptive immune function of CRISPR systems. Rodolphe received his PhD in Functional Genomics from North Carolina State University and an MBA from the University of Wisconsin, Madison.
Follow Rodolphe Barrangou:
About Intellia Therapeutics, North Carolina State University – NCSU: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Luciano Marraffini
Founder & Advisor of Intellia Therapeutics
Luciano Marraffini is an Assistant Professor of Bacteriology at Rockefeller University. Luciano’s laboratory investigates the underlying molecular mechanisms of CRISPR immunity, and seeks to employ this natural pathway to develop new technologies. He is a 2012 Rita Allen Foundation Scholar and the recipient of a 2012 NIH Director’s New Innovator Award. Luciano received his PhD from the University of Chicago where he studied bacterial pathogenesis, and completed his postdoctoral fellowship at Northwestern University.
Follow Luciano Marraffini:
About Eligo Bioscience, Intellia Therapeutics, The Rockefeller University: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Andrew Clark
Co-Founder and Chief Scientific Officer of Camallergy
Andy has been a consultant in paediatric allergy at Addenbrooke’s Hospital since 2003, gaining his MD Thesis in Allergy in the same year. He runs the paediatric allergy service at Addenbrooke’s and this work is complemented by a broad UK Government-funded research portfolio. In 2010 Andy was named in ‘The Times’ magazine list of top UK doctors, and again in 2012 he was recognised as one of the UK’s 100 best children’s specialist doctors. He plays an active role in the national parent allergy organisation (BSACI) as chair of the standards of care committee. He recently led writing guideline documents for managing egg allergy and in 2012 he was appointed chair of this committee. He now coordinates the writing of guidelines on multiple topics, such as peanut, milk and penicillin allergy, and adrenaline auto-injector use. Andy is also secretary to the taskforce on the allergic child in school, which produced European guidelines for school allergy and he is Chair of the expert scientific panel of the Anaphylaxis Campaign. Andy lectures frequently to undergraduates, primary and secondary care doctors and nurses and is a regular invited speaker at national and European allergy conferences.
Follow Andrew Clark:
About Camallergy, University of Cambridge: Camallergy develops and provides new treatments for common food allergies.
Lane Rettig
Founder of Seratis
Lane is a software developer with a passion for entrepreneurship, business and technology. He previously worked at a quant hedge fund and is currently a Wharton MBA student.
Follow Lane Rettig:
About CurrencySpot, Seratis: Communication for healthcare providers
Paulina Chilarska
CEO & Founder of Cambridge Biolabs
Chilarska’s cutting-edge work at the University of Cambridge was funded by the prestigious 4-Year Wellcome Trust PhD award in Stem Cell Biology. Already at the age of 21 she worked with the Nobel Prize winner Sir Professor Paul Nurse on the cell cycle thus investigating the mechanisms underlying carcinogenesis. Dr Chilarska is an expert in the molecular basis of ageing and strongly believes that ageing is a disease which can be prevented and treated. She is currently wirting a book describing her revolutionary approach to Ageing Prevention and Ageing Reversal. She is fluent in five languages and has international consulting experience.
Follow Paulina Chilarska:
About Cambridge Biolabs: Biotech-meets-tech startup developing personalised skincare solutions
Steven Paul
Co-Founder of Voyager Therapeutics
Steven Paul is our Interim President of R&D, a member of the Board of Directors and a Venture Partner at Third Rock Ventures. Steven Paul has had a distinguished career in neuroscience with an extensive track record in CNS drug discovery and development. He joined Third Rock in 2010, where he serves as a senior advisor to the firm and participates in the ideation and development of new companies. Steven Paul also currently leads the Appel Alzheimer’s Disease Research Institute at Weill Cornell Medical College. Preceding his appointment at Weill Cornell, Steven Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including President of the Lilly Research Laboratories, and Vice President of Discovery Research and Neuroscience Research. As President of the Lilly Research Laboratories, he was responsible for the company’s overall R&D strategy, expanding its efforts in oncology and biotechnology and resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Steven Paul served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Steven Paul has authored or co-authored more than 500 papers and book chapters. He is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. He currently serves on the board or as a trustee of several organizations, including Sage Therapeutics, Alnylam Pharmaceuticals, the Sigma Aldrich Company and the Foundation for the NIH. Steven Paul holds a B.A. in biology and psychology from Tulane University and an M.S. and M.D. from the Tulane University School of Medicine.
Follow Steven Paul:
About Karuna Therapeutics, SAGE Therapeutics, Third Rock Ventures, Voyager Therapeutics, Voyager Therapeutics: Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Cullen Buie
Co-Founder of Kytopen
Cullen R. Buie, Ph.D. is a Tenured Professor of Mechanical Engineering at MIT and co-inventor of the high-throughput genetic modification technology. He brings expertise in the areas of microfluidics, microfabrication, and experimental fluid mechanics to Kytopen.
Follow Cullen Buie:
About Kytopen, Massachusetts Institute of Technology: Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Paulo Garcia
CEO & Co-Founder of Kytopen
Dr. Paulo A. Garcia co-invented the Flowfect™ technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.
Follow Paulo Garcia:
About Kytopen: Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Nick Morrell
CEO and co-Founder of Morphogen-IX
Nick is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge, based in the Department of Medicine. He has 25 years of experience working in the field of pulmonary arterial hypertension (PAH), and is the Research Director of the National Pulmonary Hypertension Service at Papworth Hospital. His research spans clinical translational studies, experimental medicine, genetics, cell and molecular biology and preclinical models of disease. He has published over 200 papers in this field and is an internationally recognised authority on the pathobiology of PAH.
Follow Nick Morrell:
About Morphogen-IX, Papworth Hospital, University of Cambridge: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Wei Li
Co-Founder of Morphogen-IX
Wei Li, Co-Founder at MORPHOGEN-IX LIMITED.
Follow Wei Li:
About Morphogen-IX: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Ned Sahin
Co-Founder & CEO of Brain Power
Follow Ned Sahin:
About Brain Power, Harvard University, Startup Leadership Program: Brain Power builds software and hardware to transform Google Glass™ into an assistive device for people with autism.
Eric Kelsic
Founder & CEO of Dyno Therapeutics
Eric Kelsic is the Founder and CEO of Dyno Therapeutics. He is a graduate of Harvard University.
Follow Eric Kelsic:
About Dyno Therapeutics: Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Alan Crane
Co-Founder and Executive Chairman of Dyno Therapeutics
Alan Crane is the Co-Founder and Executive Chairman of Dyno Therapeutics. He earned a BA in biology, summa cum laude, an MA in biology, and an MBA from Harvard.
Follow Alan Crane:
About Arsia Therapeutics, Dyno Therapeutics, Navitor Pharmaceuticals, Pandion Therapeutics, Polaris Partners, XTuit Pharmaceuticals: Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
George Church
Co – Founder of Dyno Therapeutics
George is a Co-Founder of Dyno Therapeutics. He is also a Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology.
Follow George Church:
About Dyno Therapeutics: Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Adrian Veres
Co – Founder of Dyno Therapeutics
Adrian is a Co-Founder of Dyno Therapeutics. He obtained his Ph.D. in Systems Biology from Harvard University.
Follow Adrian Veres:
About Dyno Therapeutics: Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Tomas Bjorklund
Co-Founder & Scientific advisor of Dyno Therapeutics
Tomas Bjorklund is a Co-Founder and Scientific advisor of Dyno Therapeutics. He is also a Professor of Neuroscience at Lund University.
Follow Tomas Bjorklund:
About Dyno Therapeutics: Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Joshua Rabinowitz
Founder of Raze Therapeutics
Joshua Rabinowitz is Professor of Chemistry and Integrative Genomics at Princeton University. He is a Member of the Rutgers Cancer Institute of New Jersey and the Lewis-Sigler Institute at Princeton University. Dr. Rabinowitz’s lab studies metabolism from the system biology perspective. His group develops methods that combine mass spectrometry, isotope tracers, and mathematical modeling to quantitate metabolic flux. Using these methods, Dr. Rabinowitz attempts to understand basic principles of metabolic flux control. His lab has found that most enzyme active sites are saturated, with competition between metabolites determining enzyme activity. It is now combining metabolomics with proteomics to investigate the relative importance of active site competition, allostery, and enzyme concentrations in overall metabolic regulation. Dr. Rabinowitz’s lab is also interested in identifying the contributions of different pathways to producing key high-energy cofactors, such as ATP, NADPH, and activated one-carbon donors. Recently, it identified an unexpected tie between two of these cofactor systems, with folate metabolism playing a significant role in redox homeostasis. The lab collaborates broadly, with one notable collaboration having led to discovery of the oncometabolite 2-hydroxyglutarate. Methods developed in the lab are widely used in the cancer metabolism community.
Follow Joshua Rabinowitz:
About Raze Therapeutics: Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Vamsi Mootha
Founder of Raze Therapeutics
Vamsi Mootha is an Investigator of the Howard Hughes Medical Institute and directs a laboratory based at Massachusetts General Hospital. He is also Professor of Systems Biology and Medicine at Harvard Medical School and a Senior Associate Member of the Broad Institute. Dr. Mootha’s research is focused on mitochondria, often termed the “powerhouses of the cell.” Dr. Mootha’s group has utilized tandem mass spectrometry, computation, and biochemistry to characterize the mitochondrial proteome, which now serves as a molecular blueprint for clinical and systematic studies of mitochondria. Dr. Mootha and his colleagues have used this inventory to discover the mitochondrial calcium uniporter, a major channel of communication between mitochondria and the rest of the cell. He collaborates extensively with clinicians and researchers throughout the world, and together they have elucidated more than one dozen disease genes that underlie severe, metabolic diseases. His team has developed a number of computational tools that are used widely by the community.
Follow Vamsi Mootha:
About Raze Therapeutics: Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Frank Reynolds
Chairman of the Board, CEO, CFO, CSO & Co-Founder of PixarBio
Follow Frank Reynolds:
About PixarBio: PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products.
Eoin McKinney
Chief Scientific Officer & Co-Founder of PredictImmune
Eoin is a Wellcome-Beit intermediate Research Fellow in the Department of Medicine at the University of Cambridge and an honorary consultant in nephrology and transplantation in Cambridge University NHS hospitals Foundation Trust. He obtained a first-class degree in pre-clinical medicine from Keble College, Oxford University in 1999 and graduated in clinical medicine with honours from Edinburgh University in 2002. His primary interest is the use of systems immunology approaches to translate high throughput analyses of autoimmune disease datasets into clinical practice.
Follow Eoin McKinney:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Kenneth Smith
Co-Founder & Chief Medical Officer of PredictImmune
Professor Ken Smith is Professor of Medicine and Head of the Department of Medicine at the University of Cambridge. He trained in nephrology (FRACP, FRCP) and clinical immunology (FRCPA) and completed a PhD at the WEHI in Melbourne. His laboratory runs a translational programme in autoimmune disease (particularly inflammatory bowel disease, vasculitis and SLE) that has led to the discovery of a novel prognosis-predicting biomarker currently in clinical trials and the identification of genes and pathways involved in disease pathogenesis.
Follow Kenneth Smith:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Madhavi Gavini
CEO and Founder of Droplette
Follow Madhavi Gavini:
About Droplette: Droplette is a needle-free and hand-held device that delivers large molecules deep through skin.
Rathi Srinivas
Founder of Droplette
Follow Rathi Srinivas:
About Droplette, Novopyxis: Droplette is a needle-free and hand-held device that delivers large molecules deep through skin.
Phillip Ragon
Founder & CEO of Intersystems
Since founding InterSystems in 1978, Ragon has led the company to worldwide prominence in the database, interoperability, and healthcare application markets. Prior to starting InterSystems, Ragon co-founded a healthcare software company that became a leader in the U.S. and is now part of GE Healthcare. He has served as a healthcare IT consultant to academic and government institutions and received a prestigious Ernst & Young Entrepreneur of the Year award in healthcare information technology. Ragon is a Trustee of the Massachusetts General Hospital (MGH), where he also served as Honorary Co-Chair of the MGH Campaign. He is on the Harvard Medical School Board of Fellows. He is also a member of the MIT Corporation, the governing body of MIT, and chairs the Visiting Committee that reviews the Physics Department. In 2008, Ragon helped created the Ragon Institute, a joint research center of MGH, MIT, and Harvard. The vision of the Ragon Institute is to harness the immune system through science to prevent and cure disease, and its immediate objective is the creation of a vaccine for HIV. The son of a U.S. Air Force fighter pilot, Ragon was born in Arizona. He grew up in a variety of states and graduated from high school in Bogota, Colombia. He obtained an S.B. (B.S) in physics from MIT.
Follow Phillip Ragon:
About Intersystems: InterSystems is a vendor of software and technology for high-performance database management, integration, and health information systems.
Ariel Elizarov
Founder of Lazarus
Ariel Elizarov is the Founder at Lazarus.
Follow Ariel Elizarov:
About Lazarus: Lazarus uses patient health data to help physicians catch cancer early.
Tim Guilliams
Founder, CEO of Healx
Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK. Prior to Healx and CRDN, Tim worked on University-Industry interactions and cluster dynamics in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS). He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge, where his research related to the development of antibody fragments as novel biophysical and therapeutic tools for Parkinson’s disease. As a PhD student, Tim co-founded multiple successful student societies, including the Cambridge University Science and Policy Exchange (CUSPE), and was involved with Innovation Forum, Oxbridge Biotech Roundtable (OBR) and the Cambridge University Technology and Enterprise Club (CUTEC). He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP). Before moving to Cambridge, he obtained an MEng & BEng in Bio-Engineering from the University of Brussels (VUB).
Follow Tim Guilliams:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
David Brown
Co-Founder and Chairman of the Board of Directors of Healx
David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $30 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia. David subsequently co-founded antibody company Crescendo Biologics and serves on the boards of Healx Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He is a Trustee (Director) of two charities, Antibiotic Research UK, dedicated to solving the looming problem of antibiotic resistance; and Friends of Manjushree Vidyapith School and Orphanage, a charity he co-founded in 2005 to help destitute orphans in South Tibet.
Follow David Brown:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Richard Hall
Founder and CTO of Kokoon Technology
Richard Hall is Founder & CTO at Kokoon Technology Ltd.
Follow Richard Hall:
About Kokoon Technology: Kokoon Technology is a digital health platform applying data to provide a personalized path to better sleep and mental health
Suvrit Sra, PhD
Co-Founder & Chief AI Officer of Macro-Eyes
Follow Suvrit Sra, PhD:
About Macro-Eyes, Massachusetts Institute of Technology, Massachusetts Institute of Technology: Macro-Eyes is an AI company. Our technology makes crucial systems resilient.
Chris Torrance
Co-Founder and CEO of PhoreMost
Chris has significant oncology research and development experience, including six years as a senior manager at Cambridge-based pharmaceutical company, Vernalis. His principle expertise lies in cancer cell biology and drug discovery. In this field, he has led project teams taking drug targets from inception through to hit identification, lead optimisation and into preclinical studies. Chris holds a PhD from East Carolina University and completed a Post-Doctoral position in the world renowned oncology laboratory of Professor Bert Vogelstein (Johns Hopkins University) where he pioneered the use of X-MAN™ cancer models in high-throughput screening and drug discovery.
Follow Chris Torrance:
About PhoreMost: PhoreMost is a new-model drug discovery company based in Cambridge, UK.
David Lester
Founder of Segterra, Inc.
David has more than 25 years of experience in various health and wellness sectors. He has been recognized as a leader in personalized medicine and diagnostics for his work at Theranos, Gene Express, Pfizer, Pharmacia, and the FDA.
Follow David Lester:
About Segterra, Inc.: Segterra provides science-based personalized health analytics such as blood.
Christian Reich
Founder of Segterra, Inc.
Christian has more than 18 years of experience in life sciences research, systems biology, computational biology, and medicine. He was previously VP of Scientific Research at Genstruct and held various positions at Millennium and the European Bioinformatics Institute.
Follow Christian Reich:
About Segterra, Inc.: Segterra provides science-based personalized health analytics such as blood.
Tim Robinson
Founder of Biochemica Water
Robinson has a PhD in Environmental Biotechnology and over 13 years solid experience in water treatment. With over 20 published research articles and book chapters from his time in academia, he has specific experience in the chemistry, microbiology and process technology of industrial wastewater treatment systems. Starting his career in academia, Robinson initially developed novel methods and technologies for the treatment of industrial textile dye effluents before expanding his skill base into other areas of water treatment and beyond. Robinson is an internationally published and peer reviewed author in subjects ranging from fermentation technology, membrane bioreactors (MBRs), odour treatments, enzymatic and molecular microbiology, remediation and process technologies. He was also part of Cranfield University’s prestigious MBR and Odour research groups during his tenure as post-doctoral researcher. During his time working in the industrial sector, Robinson developed his skills in speciality chemicals and their application, as well as sales and commercial acumen. From this grew supply chain development, business strategy and company start-up skills which ultimately led to the formation of Biochemica Water Ltd with Ruddy. Robinson has a wealth of experience within the field of wastewater treatment and has a keen interest in tackling issues relating to anaerobic digestion. More recently, he spearheaded Biochemica’s environmentally-friendly division, Ecochemica. Together, Ruddy and Robinson have grown Biochemica from a fledgling business to an award-winning and nationwide operation, with interests and experience in a host of industries from food and beverage, municipal, aggregates, power generation, chemical, pharmaceutical, paper, manufacturing and more.
Follow Tim Robinson:
About Biochemica Water: Biochemica Water is the largest independently owned water treatment company,
Trey Foskett
Co-Founder and CEO of Watchmaker Genomics
Trey Foskett is the Co-Founder and CEO of Watchmaker Genomics.
Follow Trey Foskett:
About Watchmaker Genomics: Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.
Tony Kouzarides
Co-Founder of Storm Therapeutics
Tony Kouzarides is Founder at Chroma Therapeutics. He is Co-Founder at Abcam.
Follow Tony Kouzarides:
About Abcam, Cambridge Gravity, Chroma Therapeutics, Milner Therapeutics Institute, Storm Therapeutics, University of Cambridge: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Eric Miska
Co-Founder of Storm Therapeutics
Eric is the Herchel Smith Professor of Molecular Genetics and a Senior Group Leader at the Gurdon Institute at the University of Cambridge. He has an appointment as associated faculty at the Cambridge Systems Biology Centre and the Cancer Research UK Cambridge Research Institute. Eric was an EMBO Young Investigator and is a full member of EMBO since 2012. Eric is the 2013 recipient of the Hooke Medal awarded by the British Society of Cell Biology. He joined the faculty of the Wellcome Trust Sanger Institute in Hinxton in 2014 and is a Senior Investigator of the Wellcome Trust. Eric studied mathematics, physics and biology at Heidelberg, Berlin and Mainz and holds a BA in Biochemistry from Trinity College, Dublin. He received his PhD in Pathology from the University of Cambridge, UK, in 2000, working with Professor Tony Kouzarides, and was a postdoctoral fellow in the laboratory of Nobel laureate Bob Horvitz at the Massachusetts Institute of Technology, Cambridge, MA, USA from 2000 to 2004. He started his own research group at the Gurdon Institute in 2005.
Follow Eric Miska:
About Storm Therapeutics, University of Cambridge: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Shankar Balasubramian
Co-Founder and Director of Cambridge Epigenetix
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN. Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine. Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Follow Shankar Balasubramian:
About Ahren Innovation Capital, Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Thomas Weaver
Founder & CEO of PetMedix
Tom holds a PhD in Experimental Oncology and has served in a variety of research, technology development and commercial roles. He has a proven track record of creating value in highly successful start-up companies applying genome-based technologies and contract services for fundamental research, clinical, and drug discovery purposes. He has also led large infrastructure programs in genomics and animal model genetics, serving as a Director at the Medical Research Council (Oxford, UK). He trained at the University of Cambridge and MRC Lab for Molecular Biology (Cambridge, UK), and the University of Wisconsin Medical School, (Madison, USA).
Follow Thomas Weaver:
About PetMedix: PetMedix is a pet therapeutics startup.
Eric Schott
Co-Founder, Head of Translational Research and Clinical Development of Solarea Bio
Follow Eric Schott:
About Solarea Bio: Solarea Bio develops microbial therapeutics aimed to treat indications derived from chronic inflammation to aid human health.
David R. Elmaleh
Scientific Founder, CEO and Chairman of AZTherapies
David R. Elmaleh is the founder of [Mersana Therapeutics](https://www.crunchbase.com/organization/mersana-therapeutics#/entity). Previously, he served as the chairman and president of AZTherapies. Elmaleh obtained a bachelor’s degree in chemistry and physics, and master’s degree and PhD in organic chemistry from Hebrew University.
Follow David R. Elmaleh:
About AZTherapies, Mersana Therapeutics: AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Bert Vogelstein
Founder of Thrive Earlier Detection
Bert Vogelstein is a pioneer in cancer genomics, Dr. Bert Vogelstein was the first scientist to elucidate the molecular basis of a common human cancer. In particular, he and his colleagues demonstrated that colorectal tumors result from the gradual accumulation of genetic alterations in specific oncogenes and tumor suppressor genes. His group’s work on colorectal cancers forms the paradigm for much of modern cancer research, with profound implications for diagnostic and therapeutic strategies in the future. His early work on the nature of cancer genomes was dramatically confirmed when he and Thrive co-founder Kenneth W. Kinzler, Ph.D., led a team that was able to determine the sequence of every gene in colorectal, pancreatic, brain, breast and other cancers. Bert and Ken have used this information to design a new generation of screening tests for various cancer types. In the process, they invented the fundamental technologies used to identify rare mutations in clinical samples. Bert is currently the Clayton Professor of Oncology and Pathology and co-director of the Ludwig Institute at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins University School of Medicine, and is also a Howard Hughes Medical Institute Investigator. He is a member of the National Academy of Sciences, the National Academy of Medicine and the National Academy of Inventors and has held editorial positions at Science and The New England Journal of Medicine, among others. He is the recipient of numerous awards for his ground-breaking studies on the pathogenesis of human cancer, including the 2013 Breakthrough Prize in Life Sciences, The Gairdner Foundation International Award in Science, the William Allan Award from the American Society of Human Genetics and the Richard Lounsbery Award from the National Academy of Sciences.
Follow Bert Vogelstein:
About Thrive Earlier Detection: Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Nickolas Papadopoulos
Founder of Thrive Earlier Detection
Nickolas Papadopoulos is an expert in cancer diagnostics and the development of diagnostic tests. He is internationally known as a co‐discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer (HNPCC). His discovery that mutations in the mismatch repair genes predispose to HNPCC had important ramifications for the understanding of cancers with a very high rate of mutations and led to the development of diagnostic tests for the presymptomatic diagnosis of individuals with HNPCC. Nick part of the interdisciplinary team that was first to sequence all of the protein coding genes and determine genetic alterations and construct expression profiles in multiple tumors of four different common human cancers. Later, he identified novel mutations in chromatin remodeling genes, connecting genetic alterations to epigenetic changes. Currently, Nick is focused on translating the genetic information derived from cancer genome analyses to clinical applications in early detection, diagnosis and monitoring of cancer. Nick is currently professor of oncology and pathology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.
Follow Nickolas Papadopoulos:
About Thrive Earlier Detection: Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Kenneth Kinzler
Founder of Thrive Earlier Detection
Ken W. Kinzler is a world recognized expert on the molecular and genetic analysis of human cancer. He has been recognized for his role in uncovering the genetic alterations linked to the initiation of colon cancer; development of novel approaches for the molecular analysis of cancer; and more recently, for his role in deciphering the genetic blueprints of many types of cancer. In the late 2000s, Ken and Thrive co-founder Bert Vogelstein, M.D., led a team of scientists who decoded the genomes of many cancers, including breast, colon, pancreatic, brain, ovarian and liver. His work has spawned over 100 patent applications, most focused on the use of genetic approaches to improve the diagnosis and management of patients with cancers and other serious diseases. Ken is currently professor of oncology at the Johns Hopkins University School of Medicine, co-director of the Ludwig Center at Johns Hopkins University and associate director for basic research for the Sidney Kimmel Comprehensive Cancer Center (SKCCC). He is also a member of the National Academy of Sciences, National Academy of Medicine, and National Academy of Inventors and is a fellow of American Association of Cancer Research Academy. Ken is the recipient of numerous awards for his genetic analyses of human cancer, including the inaugural National Brain Tumor Society Founders Award, the 2013 American Association for Cancer Research (AACR) Team Science Award for Pancreatic Cancer Research, the 2014 AACR Team Science Award for Brain Cancer Research and the 2017 AACR Team Science Award for Liquid Biopsies. He has co-authored more than 400 peer-reviewed articles on the molecular analyses of cancer.
Follow Kenneth Kinzler:
About Thrive Earlier Detection: Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Glenn Larsen
Co-Founder, President & CEO of Aquinnah Pharmaceuticals
Glenn Larsen is a Co-Founder, President & Chief Executive Officer at Aquinnah Pharmaceuticals since 2014. Aquinnah is a pharmaceutical company focused on the development of new therapies for ALS and neurodegenerative diseases. Glenn brings significant experience from his tenure in the discovery, development and commercialization of pharmaceutical, biotech and regenerative medicines, including raising approximately $65 million in private venture funding. Glenn has been closely involved with the commercial registration of five biologics and led teams that advanced over 15 new biologic and small molecule chemical entities to clinical development. Previously, Glenn was the Vice President of Musculoskeletal Sciences at Wyeth (Pfizer); directing R&D in the fields of arthritis, pain, inflammation and tissue regeneration, including responsibility for the global development and commercial efforts of Enbrel, an anti-TNF therapeutic. Glenn also served as Vice President of Preclinical Research and Development at Genetics Institute, responsible for all preclinical activities needed to identify and advance drug candidates to clinical trials for evaluation in the fields of oncology, inflammation, immunology, hemophilia, hematopoiesis and tissue regeneration programs. Glenn currently serves on the Board of Directors of Aquinnah Pharmaceuticals, Anika Therapeutics, 180 Therapeutics and previously Hydra Biosciences; and has held prior senior executive leadership roles at Hydra Biosciences and SpringLeaf Therapeutics. Glenn received his Ph.D. in Biochemistry from Stony Brook University and is a PMD Graduate of Harvard Business School.
Follow Glenn Larsen:
About Aquinnah Pharmaceuticals: Aquinnah Pharmaceuticals is a National Institute of Neurological Disorders and Stroke
Dario Campana
Scientific Founders of Cogent Biosciences
Follow Dario Campana:
About Cogent Biosciences: Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
Brodie Stone
Co-Founder of UnifiHealth
Brodie Stone is the Co-Founder at UnifiHealth.
Follow Brodie Stone:
About UnifiHealth: UnifiHealth is reimagining how health benefits are built and delivered to small businesses.
James Heywood
Co-Founder of AOBiome
James Heywood is the co-founder and CEO at PatientsLikeMe. When his brother Stephen was diagnosed with ALS in 1999, Jamie founded the world’s first non-profit biotech, the ALS Therapy Development Institute. As its CEO for 8 years, Jamie grew ALS TDI to be the world’s largest ALS research program. He completed the first published stem cell transplant in ALS, developed a unique high throughput in vivo drug validation program, collaborated with dozens of companies, and brought 2 drugs to a clinical trial. An engineering graduate of MIT, Jamie’s unique approach to disease research and management has been profiled by Pulitzer Prize-winning author Jonathan Weiner in the biography His Brother’s Keeper, 60 Minutes, The New Yorker, and in the Sundance award-winning documentary So Much So Fast.
Follow James Heywood:
About ALS Therapy Development Institute, AOBiome, Confidential: AOBiome is a life sciences company that focuses on transforming human health.
Maya R. Said
CEO and Co-Founder of Outcomes4Me
Maya Said is the Founder and CEO of Outcomes4Me.
Follow Maya R. Said:
About Outcomes4Me: Outcomes4Me is a developer of a free mobile app and platform to navigate cancer treatment and care.
Michael Schrader
Co-Founder & CEO of Vaxess Technologies
Michael Schrader is the CEO and co-founder of Vaxess Technologies, a company revolutionizing global health by creating heat-stable vaccines. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving products for people around the world. The company was the winner of the 2013 MassTLC Innovative Life Science Technology of the Year, 2012 Harvard Business Plan Competition and The 2012 Harvard President’s Challenge for Social Entrepreneurship. Prior to founding Vaxess, Michael worked at Google, Toyota, and Honda where he has earned fifteen patents. He holds a BSME from Purdue University and an MBA from Harvard Business School.
Follow Michael Schrader:
About Harvard University, MassChallenge, Vaxess Technologies: Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Boris Mordkovich
Co-Founder & CEO of EVELO Electric Bicycles
Boris Mordkovich is the co-founder of EVELO Electric Bicycle company. As a serial entrepreneur specializing in technology and alternative transportation, his goal is to get more people on bikes more often.
Follow Boris Mordkovich:
About EVELO Electric Bicycles: Smart Electric Bicycles Delivered to Your Door.
Patrick Ohiomoba
Co-Founder and CTO of Marvin
Patrick Ohiomoba is the Co-Founder and CTO at Marvin.
Follow Patrick Ohiomoba:
About Marvin: Marvin is a virtual care platform that provides teletherapy and behavioral health services to healthcare workers.
Martin Jefson
Co-Founder, CSO of Rodin Therapeutics
Marty is chief scientific officer and co-founder of Rodin Therapeutics and Ataxion. Prior to joining Atlas Venture, Marty spent 27 years at Pfizer, most recently serving as head of neuroscience research. More than 30 development candidates were discovered during his tenure, including veranicline (Chantix), a widely used product for the treatment of nicotine addiction.
Follow Martin Jefson:
About Ataxion, Pinteon Therapeutics, Rodin Therapeutics: Rodin Therapeutics develops novel therapeutics for neurological disorders by applying insights of epigenetics.
Julian Gough
Co-Founder and Director of Genetrainer
Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.
Follow Julian Gough:
About Genetrainer, Mogrify: Genetrainer is a website that provides a personalized fitness plan for users based on their genes.
Jason Hill
Co-Founder & CEO of BeTH
Jason Hill is Founder and CEO of BeTH, a medtech start-up and pioneer of human-device interface technology aimed at delivering unprecedented healthcare savings and comfort for patients worldwide. Specific expertise in the development products that rely on novel technologies and are differentiated by human centered design. Previously principal of Sonhill Research and Design with specialty in market research, product positioning design strategy and execution for of novel technologies for various start-ups and think tank Applied Minds. Jason co-authored research framework and served as a mentor at the D-Lab at Massachusetts Institute of Technology and has lectured on design at Harvard University. Jason received a Bachelor of Science with Honors from Art Center College of Design (Pasadena) and certificate form highly selective graduate business school exchange program at INSEAD (Singapore).
Follow Jason Hill:
About BeTH: Human-device interface solutions.
Simon Read
Founder and CEO of Curie Therapeutics
Simon Read is the Founder and CEO Curie Therapeutics.
Follow Simon Read:
About Curie Therapeutics: Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Charles Kunene
Founder and CMO of River Health
Charles Kunene is the Founder and Chief Marketing Officer of River Health.
Follow Charles Kunene:
About River Health: River offers health and wellness services to businesses and individuals through its health plans.
Julie Legault
Executive Director, Founder of Amino Labs
Julie legault is the creative director, founder and ceo of amino labs inc, the company pioneering accessible bioengineering in the home and school. As a designer, julie works to make scientific and technological innovations approachable to the public, crafting experiences and products that invite culture shifts. She holds a master of art from the school of materials at the royal college of art (uk), degrees in both design technology and arts from concordia university (canada), and a masters of science from the mit media lab, massachusetts institute of technology(usa). She has taught at birmingham’s institute of art and design (uk) and worked with multi-nationals (aston martin, nokia, bombay sapphire,audi, etc), , museums, and pop stars like rihanna and imogen heap to develop smart materials, wearable technologies, and interactive art.
Follow Julie Legault:
About Amino Labs: Amino Labs is a biotechnology company that aims to make genetic engineering accessible to everyone.
Rebecca Lambert
Founder & Executive Chairman of NED Biosystems
Rebecca Lambert, founder, has over 40 years of experience designing and executing strategies to solve complex issues confronting business, government, political, healthcare and financial entities. Since 2001 she has focused on development of NED lead candidate, NED-170, as a treatment for a wide range of cancer indications. Prior to founding NED, Ms. Lambert had significant commercial successes leading an investment fund of more than $1B for Shaker Investments, and successfully launching groundbreaking telecommunications and media companies. Her Federal Government experience includes senior positions in support of political campaigns and sponsoring government policy and programs in Washington, including roles at the US Departments of Commerce, and Energy. Ms. Lambert has a BA in political science from Simmons College and completed Harvard Business School’s Advanced Management Program. For five years she served as the President of Bellevue Hospital’s Bellevue Association Board.
Follow Rebecca Lambert:
About NED Biosystems: NED Biosystems Developing proprietary combination cancer therapy. Other IP includes diagnostics.
Kevin Pojasek
Founder & Executive Chairman of Catamaran Bio
Kevin is a Venture Partner at SV Health Investors and President and CEO of Enara Bio. Prior to joining SV, Kevin was Chief Strategy and Business Officer and a member of the executive leadership team at Immunocore Ltd. In this role, he was responsible for shaping the company’s corporate, R&D and growth strategies, as well as for overseeing business development. Kevin was also co-head of the company’s Infectious Disease Unit and helped lead the Bill & Melinda Gates Foundation investment of up to $40 million. Prior to joining Immunocore, Kevin was President, Chief Executive Officer of Quartet Medicine, a company he co-founded in late 2013 while working as an Entrepreneur-in-Residence at Atlas Ventures. Kevin was also the Chief Operating Officer of Annovation Biopharma, another Atlas Ventures-funded company, which was sold to the Medicines Company in January 2015. He has also held senior executive R&D and corporate development roles at several venture capital-backed companies, including Vice President of Corporate Development at Kala Pharmaceuticals (NASDAQ:KALA) and, earlier in his career, spent time as an investment associate at PureTech Health (LSE: PRTC) an early stage venture capital firm. Kevin holds a BA from the University of Colorado Boulder, and a PhD from the Massachusetts Institute of Technology.
Follow Kevin Pojasek:
About Catamaran Bio, Enara Bio, SV Health Investors: Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies.
Daniel Carballo
CEO & Co-Founder of Encora Therapeutics
Daniel Carballo is the CEO at Encora Therapeutics.
Follow Daniel Carballo:
About Encora Therapeutics: Encora helps people with neurodegenerative movement disorders regain independence and control in their lives.
Jiang He
Co-Founder of Vizgen
Follow Jiang He:
About Vizgen: Vizgen is a biotech company that develops solutions for next-generation spatially resolved, single-cell transcriptomics.
Heather Fairhead
Founder & CEO of Phico Therapeutics
Dr Fairhead has over 17 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial. Prior to her scientific career, Heather worked for 10 years in sales and marketing in a wide range of industries.
Follow Heather Fairhead:
About Phico Therapeutics: Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Andy Fraser
Co-Founder of Camena Bioscience
Andy Fraser is the co-founder of Camena Bioscience. He is also a professor of Molecular Genetics at The University of Toronto. He was a faculty member at the Wellcome Trust Sanger Institute and performed training at the University of Cambridge and Cold Spring Harbor. Andy received his undergraduate degree in Biochemistry and Molecular Biology from Cambridge University and his Ph.D. from University College London.
Follow Andy Fraser:
About Camena Bioscience: Camena Bioscience is a synthetic biology company that develops tools to engineer new synthetic biology applications.
